Welcome to our dedicated page for MetaVia SEC filings (Ticker: MTVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MetaVia Inc. (MTVA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biotechnology issuer focused on cardiometabolic diseases. MetaVia files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-37809 as a Delaware corporation with principal offices in Cambridge, Massachusetts. These filings offer detailed information on clinical progress, financial results, capital market actions, and interactions with The Nasdaq Capital Market.
Among MetaVia’s recent filings are several Current Reports on Form 8-K that describe material events. One 8-K discusses a notice from Nasdaq regarding non-compliance with the minimum bid price requirement and a subsequent 180-day extension to May 26, 2026 to regain compliance, as well as the company’s intention to consider options such as a reverse stock split. Another 8-K references the company’s press release announcing a 1-for-11 reverse stock split of its common stock, which was implemented to help meet Nasdaq’s continued listing standards. A later press release, also furnished via 8-K, reports that MetaVia regained compliance with Nasdaq’s minimum bid price requirement and that the listing matter was closed.
Other 8-K filings furnish clinical and corporate updates, including positive Phase 2a data for vanoglipel (DA-1241) in presumed MASH patients and references to improvements in HbA1c, liver inflammation, fibrosis markers, and lipidomic profiles. MetaVia also uses Form 8-K to furnish its quarterly financial results and to provide access to updated corporate presentations, which summarize the status of its DA-1726 and vanoglipel programs and outline its cardiometabolic disease strategy.
Through Stock Titan, users can review these MetaVia SEC filings in one place and use AI-powered tools to summarize key points from complex disclosures. Filings such as 10-K annual reports, 10-Q quarterly reports, and additional 8-K current reports, when available, can help investors and analysts understand MetaVia’s R&D spending, clinical development milestones, capital structure changes, and Nasdaq listing compliance history. Insider transaction reports on Form 4, if filed, can also be accessed to see reported purchases or sales by MetaVia’s officers, directors, or significant shareholders.
Tursi James Patrick reported acquisition or exercise transactions in this Form 4 filing.
MetaVia Inc. director James Patrick Tursi received a grant of 17,186 shares of Common Stock as restricted stock units under the company’s Amended and Restated 2022 Equity Incentive Plan. These units vest on the earlier of June 8, 2027 or the day immediately prior to MetaVia’s 2027 annual stockholders meeting, contingent on his continued service. Following this award, Tursi beneficially owns 20,568 shares. The filing notes that this total reflects MetaVia’s 1-for-11 reverse stock split completed on December 4, 2025.
STRICKLAND D GORDON reported acquisition or exercise transactions in this Form 4 filing.
MetaVia Inc. director STRICKLAND D GORDON received a grant of 17,186 restricted stock units of Common Stock under the company’s Amended and Restated 2022 Equity Incentive Plan. These units vest on the earlier of June 8, 2027 or the day before the 2027 annual stockholders meeting, if he continues in service.
Following the award, he beneficially owns 21,339 shares, an amount that reflects MetaVia’s 1-for-11 reverse stock split completed on December 4, 2025. The filing shows a compensation-related equity grant rather than an open‑market trade.
Salsbury Michael reported acquisition or exercise transactions in this Form 4 filing.
MetaVia Inc. director Michael Salsbury received a grant of 17,186 restricted stock units under the company’s Amended and Restated 2022 Equity Incentive Plan. These RSUs vest on the earlier of June 8, 2027 or the day immediately prior to MetaVia’s 2027 annual stockholder meeting, contingent on his continued service.
Under the company’s non-employee director compensation policy, Salsbury elected to defer settlement of the RSUs into common shares until the earlier of just before a Change in Control, or within 60 days after his retirement, other separation from service, or death. Following this award, he beneficially owns 21,338 shares. The filing also notes prior adjustment of his holdings for a 1-for-11 reverse stock split completed on December 4, 2025.
GROVES JASON L reported acquisition or exercise transactions in this Form 4 filing.
MetaVia Inc. director Jason L. Groves received an award of 17,186 restricted stock units (RSUs) of Common Stock as equity compensation. The RSUs were granted at no cash cost and increase his direct beneficial ownership to 21,338 shares.
The RSUs vest on the earlier of June 8, 2027 or the day immediately prior to MetaVia’s 2027 annual meeting of stockholders, contingent on his continued service. Under the company’s non-employee director compensation policy, Groves elected to defer settlement of the shares until immediately before a change in control or within 60 days after his retirement, separation from service, or death. Reported holdings also reflect MetaVia’s 1-for-11 reverse stock split completed on December 4, 2025.
KOVEN ANDREW I reported acquisition or exercise transactions in this Form 4 filing.
MetaVia Inc. director Andrew I. Koven received an equity grant of 17,186 restricted stock units (RSUs) of common stock. The RSUs were granted under MetaVia's Amended and Restated 2022 Equity Incentive Plan at no cash cost to him.
The award vests on the earlier of June 8, 2027 or the day immediately prior to MetaVia's 2027 annual stockholder meeting, as long as he continues serving through that date. Koven elected to defer receipt of the underlying shares until immediately before a change in control, or within 60 days after his retirement, other separation from service, or death. Following this grant, he beneficially owns 21,339 shares, adjusted for a 1-for-11 reverse stock split completed on December 4, 2025.
Glickman Mark A reported acquisition or exercise transactions in this Form 4 filing.
MetaVia Inc. director Mark A. Glickman received a grant of 17,186 shares of Common Stock in the form of restricted stock units under the company’s Amended and Restated 2022 Equity Incentive Plan. These units vest on the earlier of June 8, 2027 or the day immediately prior to MetaVia’s 2027 annual stockholders’ meeting, subject to his continued service. Following this award, he beneficially owns 20,629 shares, reflecting adjustments from MetaVia’s 1-for-11 reverse stock split completed on December 4, 2025.
MetaVia Inc. reported results from its virtual 2026 annual stockholder meeting. Stockholders approved a first amendment to the 2022 Equity Incentive Plan, increasing the shares available for grants by 200,000 shares of common stock while leaving all other plan terms unchanged.
All five proposals on the ballot passed. Two Class I directors were elected to terms ending at the 2029 annual meeting, stockholders ratified BDO USA, P.C. as independent auditor for the 2026 fiscal year, approved a Reverse Stock Split Proposal, the equity plan amendment, and an adjournment proposal. A total of 2,866,545 shares were present and entitled to vote, constituting a quorum.
MetaVia Inc. filed an 8-K to share new obesity and metabolic disease data presented at the ADA 2026 Scientific Sessions. Phase 1 results for once-weekly dual agonist DA-1726 showed a 6.1% mean body weight reduction at Day 26 and 9.1% at Day 54 in a 48 mg cohort, with mainly mild, transient gastrointestinal side effects and no treatment-related serious events. Waist circumference fell 9.8 cm and BMI declined 3.4 kg/m² by Day 54, supporting continued obesity development and higher-dose evaluation, with additional Phase 1 titration data expected in the fourth quarter of 2026. Preclinical studies of oral GPR119 agonist vanoglipel in combination with resmetirom or metformin demonstrated synergistic weight loss, liver-protective effects, and improved glycemic control in mouse models of MASH and type 2 diabetes, reinforcing its potential as a combination backbone.
MetaVia Inc. furnished an update on its obesity and liver-disease candidate DA-1726, sharing new Phase 1 results from a 48 mg cohort presented at EASL 2026. DA-1726 is a once-weekly dual GLP1R/GCGR agonist being developed for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH).
In obese but otherwise healthy adults, once-weekly 48 mg DA-1726 without dose titration was generally well tolerated, with no serious adverse events, no treatment-related discontinuations and mainly mild-to-moderate, transient gastrointestinal side effects. No clinically meaningful changes in cardiovascular measures, including heart rate and QTcF, were seen despite glucagon receptor activation.
Participants on 48 mg DA-1726 achieved a mean body-weight reduction of 6.1% at Day 26 and 9.1% at Day 54, along with notable waist reductions. Exploratory FibroScan measures showed early, noninvasive signals of liver-related improvement versus placebo, supporting further evaluation of DA-1726 in obesity and MASH as ongoing Phase 1 titration studies continue.
MetaVia Inc. announced that three late-breaking abstracts on its cardiometabolic drug candidates DA-1726 and vanoglipel have been accepted for poster presentations at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans from June 5–8, 2026.
DA-1726 is a once-weekly injectable dual GLP1R/GCGR agonist being studied for obesity and MASH. It is currently in a 16-week Phase 1 Part 3 titration study, following a Phase 1 multiple ascending dose trial where a 32 mg dose showed strong effects on weight, glucose, and waist circumference.
Vanoglipel is a GPR119 agonist in development for MASH and type 2 diabetes. Preclinical models showed improvements in liver fat, inflammation, fibrosis, and glucose control, and Phase 1a, 1b and 2a trials reported that vanoglipel was well tolerated with evidence of direct hepatic action and glucose lowering.